Seattle Genetics Reports Brentuximab Vedotin Data at EBMT Annual Meeting

Seattle Genetics, Inc. SGEN today announced that data from a case series of Hodgkin lymphoma patients receiving brentuximab vedotin following allogeneic stem cell transplant were presented in an oral session at the European Group for Blood and Marrow TransplantationAnnual Meeting in Paris, France. Brentuximab vedotin is an antibody-drug conjugate directed to CD30, a defining marker of Hodgkin lymphoma. This is the first report of data from brentuximab vedotin in Hodgkin lymphoma patients who relapsed following allogeneic transplant. Patients in the company's pivotal Hodgkin lymphoma trial had all relapsed following autologous transplant, but none had received an allogeneic transplant. Patients relapsing following allogeneic transplant represent a particularly difficult therapeutic challenge. Key findings from this case series of 25 post-allogeneic transplant patients include: 50 percent of patients achieved an objective response (12 of 24 evaluable), including 38 percent complete remissions; an additional 42 percent of patients had stable disease Median progression-free survival (PFS) was 34 weeks; median overall survival had not been reached The median time to objective response was 8.1 weeks and patients received a median of 8 cycles of therapy; five patients remain on treatment Brentuximab vedotin administration was associated with manageable adverse events, with the most common being cough, fatigue, fever, nausea and peripheral sensory neuropathy The most common Grade 3 or higher adverse events were neutropenia, anemia, fatigue and fever